Stockhead1d
Crucible: This rare blood disease tackler plans to hit investors with its best shot
The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this ...
VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For LifeCAMPBELL, Calif., March 04, 2025 ...
WebMD24d
Hyoscyamine - Uses, Side Effects, and More
Hyoscyamine may also be used for other conditions as determined by your health care provider. Note: The FDA has not found this medicine to be safe and effective, and the label is not approved by ...
C&EN27d
Interplay of Surface Charge and Pore Characteristics in the Immobilization of Lactate Oxidase on Bulk Nanoporous Gold Electrodes
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.
Frontiers1mon
Reinforcement and MAO-A inhibition in heated tobacco products: flavor and brand variations
Objective: This study investigates the reinforcing effects and monoamine oxidase-A (MAO-A) inhibitory properties of heated tobacco products (HTPs), comparing them to nicotine alone. It also examines ...
Indiatimes1mon
Balaji Amines Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Advertisements of Extract of Standalone and Consolidated Financial Results of the Company for the Quarter ended 30th June, 2024, published in Business Standard (English) and Sakal ...